View Older Stories View More Recent Stories
-
H.C. Wainwright Reiterates Buy Rating on Inventiva SA (IVA:FP) as bbVie Collaboration Quickly Advances
-
H.C. Wainwright Downgrades CymaBay Therapeutic (CBAY) to Neutral
-
Dicerna Pharmaceuticals (DRNA) PT Raised to $30 at H.C. Wainwright
-
Paratek Pharmaceuticals (PRTK) PT Lowered to $18 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on Inventiva SA (IVA:FP)
-
Genfit (GNFT) PT Lowered to $58 at H.C. Wainwright
-
UPDATE: H.C. Wainwright Downgrades Tetraphase Pharmaceuticals (TTPH) to Neutral
-
H.C. Wainwright Starts Entasis Therapeutics (ETTX) at Buy
-
H.C. Wainwright Downgrades Melinta Therapeutics Inc. (MLNT) to Neutral Following CEO Resignation
-
H.C. Wainwright Downgrades Organovo Holdings (ONVO) to Neutral
-
Akebia Therapeutics (AKBA) PT Lowered to $17 at H.C. Wainwright
-
Akebia Therapeutics (AKBA) PT Lowered to $21 at H.C. Wainwright
-
H.C. Wainwright Starts Iterum Therapeutics (ITRM) at Buy
-
CymaBay Therapeutic (CBAY) PT Lowered to $12 at H.C. Wainwright
-
Aurinia Pharmaceuticals (AUPH) PT Raised to $25 at H.C. Wainwright On 8 Year Revenue Stream Extension
-
UPDATE: H.C. Wainwright Starts Collegium Pharmaceutical (COLL) at Buy
-
Genfit (GNFT) PT Lowered to $72 at H.C. Wainwright
-
H.C. Wainwright Starts Arcturus Therapeutics (ARCT) at Buy
-
Akebia Therapeutics (AKBA) PT Raised to $23 at H.C. Wainwright
-
H.C. Wainwright Downgrades Conatus Pharmaceuticals (CNAT) to Neutral
-
Aurinia Pharmaceuticals (AUPH) 4Q Catalyst Coming Into View - HCWainwright
-
Dicerna Pharmaceuticals (DRNA) PT Lowered to $22 at H.C. Wainwright
-
Collegium Pharmaceutical (COLL) PT Lowered to $30 at H.C. Wainwright
-
Inventiva SA (IVA:FP) Sell-Off Overdone - H.C. Wainwright
-
H.C. Wainwright Starts Albireo Pharma (ALBO) at Buy
-
Achaogen (AKAO) PT Reduced To $2 At HCWainwright
-
H.C. Wainwright Starts Inventiva SA (IVA:FP) at Buy
-
H.C. Wainwright Starts Organovo Holdings (ONVO) at Buy
-
Conatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwright
-
Paratek Pharmaceuticals (PRTK) PT Lowered to $22 at H.C. Wainwright; Keeps 'Buy'
-
H.C. Wainwright Downgrades Achaogen (AKAO) to Neutral
-
H.C. Wainwright Downgrades Trevena (TRVN) to Neutral
-
UPDATE: H.C. Wainwright Lowers Melinta Therapeutics Inc. (MLNT) PT to $12
-
AcelRx Pharmaceuticals (ACRX) PT Raised to $8 at H.C. Wainwright
-
Trevena (TRVN) PT Lowered to $3 at H.C. Wainwright
-
AcelRx (ACRX) Briefing Docs Bode Well for Vote - H.C. Wainwright
-
Dicerna Pharmaceuticals (DRNA) PT Lowered to $20 at H.C. Wainwright on Dilution
-
H.C. Wainwright Starts Melinta Therapeutics Inc. (MLNT) at Buy
-
Tetraphase Pharmaceuticals (TTPH) PT Raised to $7 at H.C. Wainwright
-
H.C. Wainwright Upgrades Dicerna Pharmaceuticals (DRNA) to Buy
-
Spero Therapeutics (SPRO) PT Lowered to $27 at H.C. Wainwright
-
Aurinia Pharmaceuticals (AUPH) PT Raised to $15 at H.C. Wainwright
-
UPDATE: H.C. Wainwright Starts Avenue Therapeutics (ATXI) at Buy, Sees Multiple NT Catalysts
-
UPDATE: Galmed Pharmaceuticals (GLMD) PT Raised to 'Street High' $43 at H.C. Wainwright
-
Madrigal Pharmaceuticals (MDGL) PT Raised to $313 at H.C. Wainwright, Sees Takeout Premium of 30% on Top of Intrinsic Fair Value
-
Madrigal Pharmaceuticals (MDGL) PT Raised to $313 at H.C. Wainwright; 'Likely Takeout Premium'
-
Madrigal Pharmaceuticals (MDGL) PT Raised to $178 at H.C. Wainwright
-
Galectin Therapeutics (GALT) PT Raised to $12 at H.C. Wainwright
-
H.C. Wainwright Starts Spero Therapeutics (SPRO) at Buy
-
CymaBay Therapeutics (CBAY) Data Leak Shows Seladelpar More Competitive With Ocliva, PT To $21 - HCWainwright

